MeSH D010300 - parkinson disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000080874:Synucleinopathies
0 Companies
0 Drugs
Success rate
D010300:Â
Parkinson disease
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| 1 A Pharma | Rivastigmine | Rivastigmine 1 A Pharma |  | 2009-12-11 |  |  |
| Abbott Biotherapeutics | Apomorphine | Taluvian |  | 2001-05-28 |  |  |
| Apomorphine | Uprima |  | 2001-05-28 |  |  | |
| AbbVie | Levodopa, Carbidopa | Duopa |  | 2015-01-09 | $233 M | Q1/23-Q1/24 |
| Acadia Pharmaceuticals | Pimavanserin | Nuplazid | 2022-07-27 | 2016-04-29 |  |  |
| Accord Healthcare | Levodopa, Carbidopa | Carbidopa Levodopa |  | 2013-02-08 |  |  |
| Pramipexole | Pramipexole Accord |  | 2011-09-29 |  |  | |
| Ropinirole | Ropinirole |  | 2017-02-28 |  |  | |
| Acorda Therapeutics | Levodopa | Inbrija | 2022-11-20 | 2018-12-21 | $5.974 M | Q2/23-Q1/24 |
| Adamas Pharmaceuticals | Amantadine | Gocovri | 2025-11-23 | 2017-08-24 |  |  |
| Amantadine | Osmolex | 2025-11-23 | 2018-02-16 |  |  | |
| Ajanta Pharma | Entacapone | Entacapone |  | 2017-08-31 |  |  |
| Alembic Pharmaceuticals | Amantadine | Amantadine |  | 2017-06-21 |  |  |
| Levodopa, Carbidopa | Carbidopa Levodopa |  | 2019-06-05 |  |  | |
| Entacapone | Entacapone |  | 2022-01-04 |  |  | |
| Pramipexole | Pramipexole |  | 2010-10-08 |  |  | |
| Ropinirole | Ropinirole |  | 2010-03-24 |  |  | |
| Alkem Laboratories | Rasagiline | Rasagiline |  | 2017-10-30 |  |  |
1
2
3
4
5
6
...
11
>
Clinical Trials
Historical Success Rate
Phase 1
64%62/97
Phase 2
46%72/155
Phase 3
59%64/108
Approved: 33Overall Success rate: 18%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
8
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use